ETX-0282
- Generic Name
- ETX-0282
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK, the Measure of How the Human Body Processes a Substance) of ETX0282 When Administered Orally to Healthy Participants
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2020-01-14
- Lead Sponsor
- Entasis Therapeutics
- Target Recruit Count
- 99
- Registration Number
- NCT03491748
- Locations
- 🇦🇺
Nucleus Network, Melbourne, Victoria, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath